

Cramer called Sarepta controversial, praised Avery Dennison and Ciena, favored ING and Santander, and declined to endorse FirstCash.
You can purchase shares of Sarepta Therapeutics (NASDAQ:SRPT) through any online brokerage.
Other companies in Sarepta Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Sarepta Therapeutics has a consensus price target of $24.52.
The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $19.1 last updated October 28, 2026 at 7:54 PM EDT.
There are no upcoming dividends for Sarepta Therapeutics.
Sarepta Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Sarepta Therapeutics.
Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The...